Candidate gene association studies of anthracycline-induced cardiotoxicity: A systematic review and meta-Analysis

Siew Lian Leong, Nathorn Chaiyakunapruk, Shaun Wen Huey Lee

Research output: Contribution to journalArticleResearchpeer-review

38 Citations (Scopus)

Abstract

Anthracyclines play an important role in the management of patients with cancer but the development of anthracycline-induced cardiotoxicity (ACT) remains a significant concern for most clinicians. Recently, genetic approach has been used to identify patients at increased risk of ACT. This systematic review assessed the association between genomic markers and ACT. A systematic literature search was performed in Medline, PubMed, Cochrane Central Register of Controlled Studies, CINAHL Plus, AMED, EMBASE and HuGE Navigator from inception until May 2016. Twenty-eight studies examining the association of genetic variants and ACT were identified. These studies examined 84 different genes and 147 single nucleotide polymorphisms. Meta-Analyses showed 3 risk variants significantly increased the risk for ACT; namely ABCC2 rs8187710 (pooled odds ratio: 2.20; 95% CI: 1.36-3.54), CYBA rs4673 (1.55; 1.05-2.30) and RAC2 rs13058338 (1.79; 1.27-2.52). The current evidence remains unclear on the potential role of pharmacogenomic screening prior to anthracycline therapy. Further research is needed to improve the diagnostic and prognostic role in predicting ACT.

Original languageEnglish
Article number39
Number of pages13
JournalScientific Reports
Volume7
DOIs
Publication statusPublished - 27 Feb 2017

Cite this